©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 115-119, 2026 ISSN: 2579-0781

https://doi.org/10.59298/IDOSR/JES/06/122115119 IDOSRJES12206

RNA Interference Therapeutics Targeting Hepatic Gluconeogenesis Pathways in Type 2 Diabetes Management

Nakawungu Catherine

Department of Pharmaceutical Microbiology and Biotechnology Kampala International University Uganda
Email: catherine.nakawungu@studwc.kiu.ac.ug

ABSTRACT

Type 2 diabetes mellitus was characterized by chronic hyperglycemia resulting from insulin resistance and impaired regulation of hepatic glucose production. Excessive hepatic gluconeogenesis was a major contributor to fasting hyperglycemia and remained incompletely controlled by conventional pharmacologic therapies. RNA interference therapeutics emerged as a promising molecular approach for selectively suppressing genes involved in hepatic glucose production. The purpose of this review was to evaluate the therapeutic potential of RNA interference strategies targeting hepatic gluconeogenic pathways in the management of Type 2 diabetes. A structured narrative review methodology was used to synthesize evidence from peer-reviewed studies examining molecular targets, delivery technologies, and metabolic outcomes of RNA interference interventions. Experimental findings demonstrated that small interfering RNA directed against key gluconeogenic regulators, including phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, forkhead box protein O1, and peroxisome proliferator-activated receptor gamma coactivator 1 alpha, reduces hepatic glucose production and improves glycemic control in preclinical models. Liver-targeted delivery systems enhanced stability and facilitated efficient gene silencing within hepatocytes. These approaches provided sustained metabolic improvements with reduced systemic toxicity compared with conventional pharmacotherapy. RNA interference therapeutics represented a promising strategy for selective regulation of hepatic metabolism in Type 2 diabetes. Continued clinical investigation and optimization of delivery systems were recommended to support translation into routine metabolic disease management.

Keywords: RNA interference, Hepatic gluconeogenesis, Type 2 diabetes, Gene silencing, siRNA therapeutics.

INTRODUCTION

Type 2 diabetes mellitus represents one of the most prevalent metabolic disorders worldwide and is a major cause of cardiovascular disease, kidney failure, and premature mortality [1, 2]. The disease is characterized by impaired insulin action in peripheral tissues combined with dysregulated hepatic glucose production. Excessive glucose output by the liver plays a central role in fasting hyperglycemia and contributes substantially to overall glycemic burden in affected individuals. Hepatic gluconeogenesis is tightly regulated under physiological conditions through coordinated hormonal and transcriptional mechanisms. In Type 2 diabetes, insulin resistance and altered signaling pathways lead to persistent activation of gluconeogenic enzymes, resulting in inappropriate glucose release into the circulation [3].

Conventional antidiabetic therapies such as metformin and insulin sensitizers reduce hepatic glucose production indirectly through modulation of cellular energy status or insulin signaling [4]. However, these approaches do not specifically target the molecular regulators responsible for increased gluconeogenesis. Many patients continue to exhibit elevated fasting glucose levels despite combination therapy, and treatment-associated adverse effects may limit therapeutic intensification. These limitations highlight the need for innovative strategies that directly regulate hepatic metabolic pathways at the molecular level.

RNA interference therapeutics offer a highly specific approach to suppressing expression of genes involved in hepatic glucose production [5]. By selectively degrading messenger RNA transcripts, small interfering RNA molecules can reduce synthesis of key gluconeogenic enzymes and transcription factors. This review examines the biochemical regulation of hepatic gluconeogenesis, the molecular basis of RNA interference therapeutics, key gene targets for intervention, experimental and translational evidence supporting this approach, and the therapeutic opportunities and challenges associated with RNA interference-based treatments. The purpose of this study is to evaluate RNA interference therapeutics targeting hepatic gluconeogenic pathways as a novel strategy for improving glycemic control in Type 2 diabetes management.

Biochemical Regulation of Hepatic Gluconeogenesis in Type 2 Diabetes

Hepatic gluconeogenesis is an essential metabolic pathway that maintains blood glucose concentrations during fasting [6]. The process involves synthesis of glucose from non-carbohydrate precursors, including lactate derived from anaerobic glycolysis, glycerol released from adipose tissue lipolysis, and glucogenic amino acids obtained from protein metabolism. Under normal physiological conditions, hepatic gluconeogenesis is precisely regulated to balance glucose production with peripheral utilization.

Several key enzymes control the rate of gluconeogenesis. Phosphoenolpyruvate carboxykinase catalyzes the conversion of oxaloacetate to phosphoenolpyruvate and represents a major regulatory step in glucose synthesis [7, 8]. Fructose 1 6 bisphosphatase hydrolyzes fructose 1 6 bisphosphate to fructose 6-phosphate, bypassing the irreversible phosphofructokinase reaction of glycolysis. Glucose 6 phosphatase catalyzes the final step in gluconeogenesis by converting glucose 6 phosphate into free glucose that can be released into the circulation.

Hormonal regulation plays a critical role in controlling gluconeogenesis. Insulin suppresses hepatic glucose production by inhibiting transcription of gluconeogenic enzymes and promoting glycogen synthesis [9]. Glucagon exerts the opposite effect by stimulating cyclic AMP signaling pathways that activate gluconeogenic gene expression. In Type 2 diabetes, insulin resistance reduces the inhibitory effects of insulin while glucagon signaling remains relatively preserved, resulting in persistent activation of gluconeogenic pathways [10, 11].

Transcriptional regulators coordinate long-term control of gluconeogenesis. Forkhead box protein O1 promotes expression of gluconeogenic enzymes under fasting conditions [12], while peroxisome proliferator activated receptor gamma coactivator 1 alpha enhances transcriptional activity of multiple metabolic regulators. Increased activity of these transcription factors contributes to excessive glucose production in Type 2 diabetes. Dysregulation of these molecular pathways provides important targets for therapeutic intervention.

RNA Interference Therapeutics: Molecular Mechanisms and Delivery Strategies

RNA interference is a naturally occurring cellular mechanism that regulates gene expression through sequence specific degradation of messenger RNA [13]. Therapeutic RNA interference typically involves the use of small interfering RNA molecules designed to target specific gene transcripts. These double-stranded RNA molecules enter cells through endocytosis and are incorporated into the RNA-induced silencing complex. The antisense strand guides the complex to complementary messenger RNA sequences, resulting in cleavage and degradation of the target transcript.

Gene silencing through RNA interference reduces production of the encoded protein without altering genomic DNA [14]. This mechanism allows selective suppression of disease-associated genes while preserving normal cellular functions. The specificity of nucleotide sequence recognition minimizes unintended effects on unrelated pathways when carefully designed molecules are used. Efficient delivery to hepatocytes is essential for therapeutic success in metabolic diseases. Lipid nanoparticle systems protect small interfering RNA molecules from degradation in the circulation and promote cellular uptake through endocytic mechanisms [15, 16,17-20]. After internalization, release of RNA molecules into the cytoplasm allows interaction with the silencing complex.

Ligand-mediated targeting strategies improve delivery specificity. Conjugation of small interfering RNA molecules to N-acetylgalactosamine residues promotes binding to asialoglycoprotein receptors expressed on hepatocytes [17, 18,21-25]. Receptor-mediated uptake increases intracellular concentrations within the liver while limiting systemic exposure. Chemical modification of RNA molecules improves stability and prolongs duration of action. Alterations in ribose structure and backbone chemistry reduce susceptibility to nuclease degradation. These advances have enabled sustained gene silencing after infrequent dosing, making RNA interference therapeutics suitable for chronic metabolic disorders.

RNA Interference Targets in Hepatic Gluconeogenesis

Several molecular targets within hepatic gluconeogenesis have been investigated for RNA interference-based therapy. Phosphoenolpyruvate carboxykinase represents one of the most extensively studied targets because of its central role in glucose synthesis. Silencing of phosphoenolpyruvate carboxykinase expression reduces conversion of oxaloacetate to phosphoenolpyruvate, thereby limiting flux through the gluconeogenic pathway. Experimental studies demonstrate significant reductions in fasting glucose concentrations following suppression of this enzyme. Glucose 6 phosphatase is another critical target because it controls the final step of hepatic glucose production. Inhibition of glucose 6 phosphatase prevents release of newly synthesized glucose into the circulation. RNA

interference directed against this enzyme reduces hepatic glucose output and improves metabolic control in experimental models [19,26-30].

Transcriptional regulators provide additional opportunities for intervention. Forkhead box protein O1 coordinates expression of multiple gluconeogenic genes, and its suppression results in simultaneous reduction of several enzymes involved in glucose production. Silencing of forkhead box protein O1 improves insulin sensitivity and decreases hepatic glucose output. Peroxisome proliferator activated receptor gamma coactivator 1 alpha enhances transcriptional activity of metabolic regulators involved in gluconeogenesis [20]. RNA interference targeting this coactivator reduces expression of several gluconeogenic enzymes and improves glycemic control in experimental systems.

Targeting transcriptional regulators may produce broader metabolic effects than inhibition of individual enzymes. However, selective modulation is required to avoid disruption of essential metabolic processes. These targets illustrate the flexibility of RNA interference approaches for regulating hepatic glucose production.

Preclinical and Emerging Clinical Evidence

Preclinical studies provide substantial support for RNA interference-based suppression of hepatic gluconeogenesis. In rodent models of Type 2 diabetes, administration of small interfering RNA targeting gluconeogenic enzymes produces significant reductions in fasting glucose levels [21]. Improvements in glucose tolerance have also been observed, indicating enhanced metabolic control. Pharmacokinetic studies demonstrate efficient uptake of RNA interference molecules by hepatocytes when delivered through lipid nanoparticle systems or receptor-targeted conjugates. Sustained gene silencing lasting several weeks has been reported following single administrations in experimental animals. Prolonged suppression of target genes results in stable reductions in hepatic glucose production.

RNA interference therapies may also influence glycogen metabolism. Reduced gluconeogenic activity is often accompanied by increased glycogen storage within hepatocytes, reflecting improved regulation of glucose flux. These changes contribute to improved overall glucose homeostasis. Safety evaluations in experimental models generally indicate acceptable tolerability. Liver enzyme concentrations typically remain within normal ranges, and histological examinations reveal minimal structural abnormalities. Nevertheless, long-term safety data remain limited.

Early clinical investigations of liver-targeted RNA interference therapies for metabolic diseases demonstrate favorable pharmacokinetic characteristics and sustained gene silencing [22]. Although most clinical studies have focused on lipid metabolism, the results support the feasibility of RNA interference approaches for hepatic metabolic regulation.

Therapeutic Potential, Limitations, and Future Directions

RNA interference therapeutics offer several advantages compared with conventional pharmacologic treatments. Direct suppression of gluconeogenic genes provides a highly specific approach to controlling hepatic glucose production [23]. Long duration of action allows infrequent dosing, which may improve treatment adherence. Precision targeting of hepatocytes reduces systemic drug exposure and limits off-target toxicity. Selective modulation of metabolic pathways may produce more predictable therapeutic responses than indirect pharmacologic interventions. These characteristics make RNA interference therapeutics particularly attractive for chronic metabolic diseases.

Despite these advantages, important challenges remain. Off-target gene silencing may occur if RNA sequences share partial homology with unintended transcripts. Activation of innate immune responses by RNA molecules may produce inflammatory reactions in some individuals [24]. Manufacturing complexity and cost may limit accessibility, particularly in low-resource settings. Large-scale production requires specialized technologies and rigorous quality control procedures. Regulatory approval will require demonstration of long-term safety and consistent therapeutic benefit.

Future research should focus on optimization of delivery systems, identification of additional molecular targets, and evaluation of combination approaches with existing therapies. Improved understanding of hepatic metabolic regulation will support development of more effective RNA interference strategies.

CONCLUSION

Excessive hepatic gluconeogenesis plays a central role in the pathogenesis of fasting hyperglycemia in Type 2 diabetes and remains inadequately controlled by conventional pharmacologic therapies. RNA interference therapeutics provide a mechanistically precise approach to suppressing expression of genes responsible for increased hepatic glucose production. By targeting key enzymes and transcriptional regulators, small interfering RNA molecules reduce gluconeogenic flux and improve metabolic control in experimental models. Advances in liver-targeted delivery systems have improved stability and specificity of RNA interference therapeutics, enabling efficient gene silencing within hepatocytes. Sustained suppression of gluconeogenic pathways offers the potential for long-lasting improvements in glycemic regulation with reduced systemic toxicity. Preclinical findings and emerging clinical experience support the feasibility of this approach as a novel therapeutic strategy for metabolic disease.

Further investigation is required to establish long-term safety, optimize delivery technologies, and evaluate therapeutic effectiveness in large clinical trials. RNA interference therapeutics targeting hepatic gluconeogenesis should be advanced into clinical development as a precision strategy for improving glycemic control in Type 2 diabetes.

REFERENCES

1. Dal Canto, E., Ceriello, A., Rydén, L., Ferrini, M., Hansen, T.B., Schnell, O., Standl, E., Beulens, J.W.: Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur. J. Prev. Cardiol. 26, 25–32 (2019). https://doi.org/10.1177/2047487319878371
2. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
3. Czech, M.P.: Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 23, 804–814 (2017). https://doi.org/10.1038/nm.4350
4. Foretz, M., Guigas, B., Viollet, B.: Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 15, 569–589 (2019). https://doi.org/10.1038/s41574-019-0242-2
5. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
6. Scoditti, E., Sabatini, S., Carli, F., Gastaldelli, A.: Hepatic glucose metabolism in the steatotic liver. Nat Rev Gastroenterol Hepatol. 21, 319–334 (2024). https://doi.org/10.1038/s41575-023-00888-8
7. Yu, S., Meng, S., Xiang, M., Ma, H.: Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis. Molecular Metabolism. 53, 101257 (2021). https://doi.org/10.1016/j.molmet.2021.101257
8. Koendjbiharie, J.G., van Kranenburg, R., Kengen, S.W.M.: The PEP-pyruvate-oxaloacetate node: variation at the heart of metabolism. FEMS Microbiol Rev. 45, fuaa061 (2021). https://doi.org/10.1093/femsre/fuaa061
9. Lewis, G.F., Carpentier, A.C., Pereira, S., Hahn, M., Giacca, A.: Direct and indirect control of hepatic glucose production by insulin. Cell Metabolism. 33, 709–720 (2021). https://doi.org/10.1016/j.cmet.2021.03.007
10. Czech, M.P.: Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 23, 804–814 (2017). https://doi.org/10.1038/nm.4350
11. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
12. Sha, X., Zou, X., Liu, S., Guan, C., Shi, W., Gao, J., Zhong, X., Jiang, X.: Forkhead box O1 in metabolic dysfunction-associated fatty liver disease: molecular mechanisms and drug research. Front. Nutr. 11, (2024). https://doi.org/10.3389/fnut.2024.1426780
13. Xu, W., Jiang, X., Huang, L.: RNA Interference Technology. Comprehensive Biotechnology. 560–575 (2019). https://doi.org/10.1016/B978-0-444-64046-8.00282-2
14. Malakondaiah, S., Julius, A., Ponnambalam, D., Gunthoti, S.S., Ashok, J., Krishana, P.S., Rebecca, J.: Gene silencing by RNA interference: a review. GENOME INSTAB. DIS. 5, 225–241 (2024). https://doi.org/10.1007/s42764-024-00135-7
15. Hou, X., Zaks, T., Langer, R., Dong, Y.: Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 6, 1078–1094 (2021). https://doi.org/10.1038/s41578-021-00358-0
16. Ahmed, T.: Lipid nanoparticle mediated small interfering RNA delivery as a potential therapy for Alzheimer's disease. European Journal of Neuroscience. 59, 2915–2954 (2024). https://doi.org/10.1111/ejn.16336
17. Tanowitz, M., Hettrick, L., Revenko, A., Kinberger, G.A., Prakash, T.P., Seth, P.P.: Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res. 45, 12388–12400 (2017). https://doi.org/10.1093/nar/gkx960
18. Humphreys, S.C., Thayer, M.B., Lade, J.M., Wu, B., Sham, K., Basiri, B., Hao, Y., Huang, X., Smith, R., Rock, B.M.: Plasma and Liver Protein Binding of *N*-Acetylgalactosamine–Conjugated Small Interfering RNA. Drug Metabolism and Disposition. 47, 1174–1182 (2019). https://doi.org/10.1124/dmd.119.086967
19. Alkhouri, N., Gawrieh, S.: A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opinion on Investigational Drugs. 30, 237–244 (2021). https://doi.org/10.1080/13543784.2021.1879792
20. Abdelazem, A.S., Assaf, S.A.F.M., Hussein, A.G., Mousa, M.M.: Influence of Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha (PGC-1α) in Type 2 Diabetes: Review Article. The Egyptian Journal of Hospital Medicine. (2022). https://doi.org/10.21608/ejhm.2022.233186
21. Wei, S., Zhang, M., Yu, Y., Xue, H., Lan, X., Liu, S., Hatch, G., Chen, L.: HNF-4α regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-

treated HepG2 cells. European Journal of Pharmacology. 791, 254–263 (2016). https://doi.org/10.1016/j.ejphar.2016.08.038
22. Alkhouri, N., Gawrieh, S.: A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opinion on Investigational Drugs. 30, 237–244 (2021). https://doi.org/10.1080/13543784.2021.1879792
23. Zhang, X., Yang, S., Chen, J., Su, Z.: Unraveling the Regulation of Hepatic Gluconeogenesis. Front. Endocrinol. 9, (2019). https://doi.org/10.3389/fendo.2018.00802
24. Nejad, C., Stunden, H.J., Gantier, M.P.: A guide to miRNAs in inflammation and innate immune responses. The FEBS Journal. 285, 3695–3716 (2018). https://doi.org/10.1111/febs.14482
25. Ugwu OPC, Okon MB, Ogenyi FC, Ugwu CN, Ugwu JN. Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: progress, evidence gaps, and translational pathways for durable and scalable immunization. Hum Vaccin Immunother. 2026;22(1):2661120.
26. Ugwu OPC, Okon MB, Ogenyi FC, Ugwu CN, Ugwu JN. Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases. Front Immunol. 2026;17:1758902.
27. Ugwu OPC, Ogenyi FC, Basajja M, Ugwu CN, Okon MB. Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review. Front Drug Deliv. 2026;6:1793322.
28. Okon MB, Ugwu OPC, Ugwu CN, Ogenyi FC, Swase DT, Anyanwu CN, et al. From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats. Front Public Health. 2025;13:1711344.
29. Okon MB, Olorunnisola SO, Ifie JE, Ugwu OPC, Alum EU. Transgenerational reproductive risks of BPA: epigenetic mechanisms and biomarker applications. A critical review. Environ Epigenet. 2026:dvag010.
30. Okon MB, Ugwu OPC, Ugwu CN, Ogenyi FC, Swase DT, Alum EU, et al. Endocrine disruption rewards: bisphenol-A-induced reproductive toxicity and the precision ameliorative potential of flavonoids in preclinical studies. A systematic review and meta-analysis. Front Toxicol. 2025;7:1687862.

CITE AS: Nakawungu Catherine (2026). RNA Interference Therapeutics Targeting Hepatic Gluconeogenesis Pathways in Type 2 Diabetes Management. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 115-119.
https://doi.org/10.59298/IDOSR/JES/06/122115119